Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

16/03/2026

📣This 𝐂𝐑𝐂 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, we want to spotlight how essential the use of standardized, validated MSI testing is for guiding therapy in mCRC.

The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐂𝐃𝐱 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭 delivers:
• Fully automated, sample-to-result workflow
• ~150 min. TAT with

13/03/2026

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗨𝗦𝗖𝗔𝗣 𝟮𝟬𝟮𝟲!
📅 21-26 March |📍Booth 755 | 🗺️ San Antonio, TX, USA

Stop by booth 755 and learn more about getting your molecular biomarker results in only 3 hours on the fully automated Idylla™ Platform⏱️

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en-US/news-events/events/uscap-2026

13/03/2026

We're attending the 𝗢𝗚𝗣𝗮𝘁𝗵 𝗦𝗽𝗿𝗶𝗻𝗴 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲!
📅 13-14 March | 🗺️ Vienna, Austria

Come and say hi! Dr. Manfred & Dr. Edgar are eager to show you Idylla™, a fully automated platform that generates molecular biomarker results in only 3 hours⏱️
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/gh9nKbMA

13/03/2026

𝗟𝗶𝘃𝗲 𝗳𝗿𝗼𝗺 #𝗗𝗣𝗔𝗦 𝗔𝗿𝘀𝗺ø𝗱𝗲 𝟮𝟬𝟮𝟲!
📅 12-14 March | 🗺️ Kolding, Denmark

Come meet Cyriel and learn more about getting your molecular biomarker results in only 3 hours with Idylla™ ⏱️
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/meet-idylla

12/03/2026

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1103_meet-idylla

11/03/2026

💡 𝐌𝐚𝐫𝐜𝐡 𝐢𝐬 𝐂𝐑𝐂 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, a reminder of the critical role of standardized, validated MSI testing in treatment decisions for CRC patients.

In the 𝐂𝐡𝐞𝐜𝐤𝐌𝐚𝐭𝐞-𝟖𝐇𝐖 𝐭𝐫𝐢𝐚𝐥*, 17% of patients identified as MSI-H/dMMR by local testing were 𝐜𝐥𝐚𝐬𝐬𝐢𝐟𝐢𝐞𝐝 𝐚𝐬 𝐌𝐒𝐒 𝐛𝐲 𝐭𝐡𝐞 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐂𝐃𝐱 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭 — demonstrating how standardized testing can uncover misclassifications and support more confident therapy selection.

The Idylla™ CDx MSI Test is a fully automated, sample-to-result companion diagnostic to provide rapid, standardized, and reliable MSI results for mCRC patients.

𝐒𝐭𝐚𝐫𝐭 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐧𝐨𝐰 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-cdx-msi-test

*https://www.biocartis.com/en/reference-march-is-crc-awareness-month-1

10/03/2026

📢 𝗣𝗥𝗘𝗦𝗦 𝗡𝗘𝗪𝗦: 𝗕𝗶𝗼𝗰𝗮𝗿𝘁𝗶𝘀 𝗥𝗲𝗰𝗲𝗶𝘃𝗲𝘀 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗜𝗩𝗗𝗥 𝗖𝗲𝗿𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁
We’re excited to announce that the Idylla™ CDx MSI Test has received Class C companion diagnostic (CDx) certification under the EU’s IVDR as a CDx for colorectal cancer (CRC)!

The Test is indicated as an aid to identify adult patients with microsatellite instability-high (𝗠𝗦𝗜-𝗛) 𝗺𝗲𝘁𝗮𝘀𝘁𝗮𝘁𝗶𝗰 𝗖𝗥𝗖 patients, who may benefit from treatment with 𝗻𝗶𝘃𝗼𝗹𝘂𝗺𝗮𝗯 in combination with 𝗶𝗽𝗶𝗹𝗶𝗺𝘂𝗺𝗮𝗯.

The IVDR-certified Idylla™ CDx MSI Test will be 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝘀𝗼𝗼𝗻 to customers across Europe and additional regions where IVDR regulations apply. The Idylla™ CDx MSI Test is already commercially available in the US.

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗧𝗲𝘀𝘁: https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-cdx-msi-test
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://www.biocartis.com/en/press-events/press-releases

𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘊𝘋𝘹 𝘔𝘚𝘐 𝘛𝘦𝘴𝘵 (𝘈0220/6) 𝘪𝘴 𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘪𝘴 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚 𝘶𝘯𝘥𝘦𝘳 𝘗250005.

05/03/2026

💡𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗮 𝗳𝗮𝘀𝘁, 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘄𝗮𝘆 𝘁𝗼 𝗱𝗲𝘁𝗲𝗰𝘁 𝗣𝗜𝗞𝟯𝗖𝗔 & 𝗔𝗞𝗧𝟭 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀?

Discover the 𝗨𝗣𝗗𝗔𝗧𝗘𝗗 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗜𝗞𝟯𝗖𝗔-𝗔𝗞𝗧𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆:
✅ 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗰𝗼𝘃𝗲𝗿𝗮𝗴𝗲: Detection of 13 PIK3CA mutations and 1 AKT1 mutation
✅ 𝗠𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: Directly from 1 FFPE tissue section (5 - 10 µm) with hands-on time under 3 minutes
✅ 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄: Single-use cartridge, cost-effective, no batching required
✅ 𝗣𝗿𝗼𝘃𝗲𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆: 97% overall concordance versus NGS and real-time PCR tests*

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/research/research-assays/idylla-pik3ca-akt1-mutation-assay-0

For Research Use Only (RUO), not for use in diagnostic procedures.

03/03/2026

𝐓𝐫𝐢𝐩𝐥𝐞 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 (𝐓𝐍𝐁𝐂) 𝐢𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐚𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐟𝐨𝐫𝐦𝐬 𝐨𝐟 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 ❗❗

TNBC patients lack ER, PR and HER2 receptor biomarkers, which can complicate their treatment plan. We support and hear these patients! 🙌

Check out our website for more information on our Breast Cancer Assay Portfolio (RUO*) 👉 https://www.biocartis.com/en/breast-cancer-assay-portfolio?utm_source=facebook&utm_medium=social&utm_campaign=0303_breast-cancer-assay-portfolio

*For Research Use Only (RUO), not for use in diagnostic procedures.
Triple Negative Breast Cancer Foundation

02/03/2026

Did you know that colorectal cancer (CRC) is the second leading cause of cancer death worldwide? 🌎

March is , a month focused on spreading the word and sharing stories on CRC 💙 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐚𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐚𝐧𝐝 𝐦𝐚𝐤𝐞 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞!

👉 Find out more about our Idylla™ CRC Test Portfolio https://www.biocartis.com/en/oncology/for-oncologists/idylla-for-colorectal-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0203_idylla-for-colorectal-cancer

27/02/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy.

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay.

👉 Read morehttps://biocartis.com/sites/default/files/2024-09/colorectal-leaflet-august2024.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

25/02/2026

⏱️ Delayed or limited access to molecular testing results such as MSI/MMR can lead to patient anxiety, suboptimal treatment decisions and disparities in outcomes*.

💡 Real-world evidence has demonstrated that 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗠𝗦𝗜 is a 𝗯𝗲𝘁𝘁𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗲𝘁𝗵𝗼𝗱 than IHC to 𝗽𝗿𝗲𝗱𝗶𝗰𝘁 𝗧𝗧𝗡𝗧, 𝗣𝗙𝗦 𝗮𝗻𝗱 𝗢𝗦 𝘄𝗶𝘁𝗵 𝗜𝗖𝗜**.

👉 The 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 is a fast testing solution that fits any hospital setting, helping overcome testing barriers, support equitable care and ensure optimal CRC patient outcomes. Learn more: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test

Approved in the US under P250005.
* https://doi.org/10.1200/JCO.2025.43.16_suppl.3568; https://doi.org/10.1200/JCO.2024.42.3_suppl.29; https://doi.org/10.1097/01.COT.0000723664.21999.cc
** https://doi.org/10.1001/jamanetworkopen.2022.52244

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.